Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin, … , Alan J. Korman, Hassane M. Zarour
Joe-Marc Chauvin, … , Alan J. Korman, Hassane M. Zarour
Published April 13, 2015
Citation Information: J Clin Invest. 2015;125(5):2046-2058. https://doi.org/10.1172/JCI80445.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 31

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

  • Text
  • PDF
Abstract

T cell Ig and ITIM domain (TIGIT) is an inhibitory receptor expressed by activated T cells, Tregs, and NK cells. Here, we determined that TIGIT is upregulated on tumor antigen–specific (TA-specific) CD8+ T cells and CD8+ tumor-infiltrating lymphocytes (TILs) from patients with melanoma, and these TIGIT-expressing CD8+ T cells often coexpress the inhibitory receptor PD-1. Moreover, CD8+ TILs from patients exhibited downregulation of the costimulatory molecule CD226, which competes with TIGIT for the same ligand, supporting a TIGIT/CD226 imbalance in metastatic melanoma. TIGIT marked early T cell activation and was further upregulated by T cells upon PD-1 blockade and in dysfunctional PD-1+TIM-3+ TA-specific CD8+ T cells. PD-1+TIGIT+, PD-1–TIGIT+, and PD-1+TIGIT– CD8+ TILs had similar functional capacities ex vivo, suggesting that TIGIT alone, or together with PD-1, is not indicative of T cell dysfunction. However, in the presence of TIGIT ligand–expressing cells, TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of both TA-specific CD8+ T cells and CD8+ TILs. Collectively, our results show that TIGIT and PD-1 regulate the expansion and function of TA-specific CD8+ T cells and CD8+ TILs in melanoma patients and suggest that dual TIGIT and PD-1 blockade should be further explored to elicit potent antitumor CD8+ T cell responses in patients with advanced melanoma.

Authors

Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2009 Total
Citations: 15 51 66 56 68 51 38 36 30 18 8 1 438
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2022 (56)

Title and authors Publication Year
Structural and functional characterization of a monoclonal antibody blocking TIGIT
B Jeong, H Nam, J Lee, H Park, K Cho, J Sheen, E Song, M Oh, S Lee, H Choi, J Yang, M Kim, B Oh
mAbs 2022
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
X Chen, L Xue, X Ding, J Zhang, L Jiang, S Liu, H Hou, B Jiang, L Cheng, Q Zhu, L Zhang, X Zhou, J Ma, Q Liu, Y Li, Z Ren, B Jiang, X Song, J Song, W Jin, M Wei, Z Shen, X Liu, L Wang, K Li, T Zhang
Frontiers in immunology 2022
Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
S Rovers, A Janssens, J Raskin, P Pauwels, J van Meerbeeck, E Smits, E Marcq
Biomedicines 2022
DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
D Niebel, A Fröhlich, R Zarbl, S Fietz, L de Vos, T Vogt, J Dietrich, J Sirokay, P Kuster, G Saavedra, S Valladolid, F Hoffmann, S Strieth, J Landsberg, D Dietrich
Clinical Epigenetics 2022
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
E Chiang, I Mellman
Journal for ImmunoTherapy of Cancer 2022
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
K Liu, J Cui, Y Zhan, Q Ouyang, Q Lu, D Yang, X Li, J Yin
Molecular Cancer 2022
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
F Comito, R Pagani, G Grilli, F Sperandi, A Ardizzoni, B Melotti
Cancers 2022
Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma
C Luo, H Nie, L Yu, M Georgieva
Oxidative Medicine & Cellular Longevity 2022
Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
X Chen, W Zhang, W Yang, M Zhou, F Liu
Aging 2022
Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade
A Gorzo, D Galos, S Volovat, C Lungulescu, C Burz, D Sur
Life Sciences 2022
PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours
M Davern, M Fitzgerald, C Buckley, A Heeran, N Donlon, J McGrath, F Connell, M Deshpande, C Hayes, J MacDonald, A Sheppard, J Reynolds, S Maher, N Lynam-Lennon, B Murphy, J Lysaght
Translational oncology 2022
hDirect-MAP: projection-free single-cell modeling of response to checkpoint immunotherapy
Y Lu, G Xue, N Zheng, K Han, W Yang, R Wang, L Wu, L Miller, T Pardee, P Triozzi, H Lo, K Watabe, S Wong, B Pasche, W Zhang, G Jin
Briefings in Bioinformatics 2022
Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
P Weimer, J Wellbrock, T Sturmheit, L Oliveira-Ferrer, Y Ding, S Menzel, M Witt, L Hell, B Schmalfeldt, C Bokemeyer, W Fiedler, F Brauneck
Cells 2022
Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
D Murakami, K Matsuda, H Iwamoto, Y Mitani, Y Mizumoto, Y Nakamura, I Matsuzaki, R Iwamoto, Y Takahashi, F Kojima, S Murata, H Yamaue, N Miyoshi
PloS one 2022
Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
D Wang, Y Gu, X Yan, C Huo, G Wang, Y Zhao, M Teng, Y Li
Frontiers in Oncology 2022
Natural killer cells: a promising immunotherapy for cancer
J Chu, F Gao, M Yan, S Zhao, Z Yan, B Shi, Y Liu
Journal of Translational Medicine 2022
Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma
C Zhu, Q Wu, N Yang, Z Zheng, F Zhou, Y Zhou
Frontiers in Genetics 2022
Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer
L Liu, A Wang, X Liu, S Han, Y Sun, J Zhang, L Guo, Y Zhang
Journal of Translational Medicine 2022
PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
Zhang H, Tan S, Fang C, Zhang Q, Cao X, Liu Y
Frontiers in Oncology 2022
Update in TIGIT Immune-Checkpoint Role in Cancer
Annese T, Tamma R, Ribatti D
Frontiers in Oncology 2022
TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
Yue C, Gao S, Li S, Xing Z, Qian H, Hu Y, Wang W, Hua C
Frontiers in immunology 2022
Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
Kang BH, Lee HK
International journal of molecular sciences 2022
Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
Rossetti R, Brand H, Lima SC, Furtado IP, Silveira RM, Fantacini DM, Covas DT, de Souza LE
2022
TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.
Zhao K, Jiang L, Si Y, Zhou S, Huang Z, Meng X
Cancer Immunology, Immunotherapy 2022
Recent Advances and Challenges in Uveal Melanoma Immunotherapy.
Fu Y, Xiao W, Mao Y
Cancers 2022
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights.
Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W
Acta Pharmacologica Sinica 2022
PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
Yang Z, Peng Y, Xu J, Chen P, Zhao Z, Cai Q, Li L, Tian H, Bai G, Liu L, Gao S, He J
Translational oncology 2022
TIGIT Deficiency Protects Mice From DSS-Induced Colitis by Regulating IL-17A–Producing CD4+ Tissue-Resident Memory T Cells
Chen B, Ye B, Li M, Wang S, Li J, Lai Y, Yang N, Ke Z, Zhang H
Frontiers in immunology 2022
Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
Lao Y, Shen D, Zhang W, He R, Jiang M
Cancers 2022
Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy
Ghaderi SS, Riazi-Rad F, Qamsari ES, Bagheri S, Rahimi-Jamnani F, Sharifzadeh Z
BMC Biotechnology 2022
Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy.
Ducoin K, Bilonda-Mutala L, Deleine C, Oger R, Duchalais E, Jouand N, Bossard C, Jarry A, Gervois-Segain N
Cancers 2022
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.
Wang DR, Wu XL, Sun YL
Signal Transduction and Targeted Therapy 2022
Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma
Pham NB, Abraham N, Velankar KY, Schueller NR, Philip EJ, Jaber Y, Gawalt ES, Fan Y, Pal SK, Meng WS
2022
Advanced Acral Melanoma Therapies: Current Status and Future Directions.
Zhang Y, Lan S, Wu D
Current Treatment Options in Oncology 2022
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu L, Sun M, Zhang Q, Zhou Q, Wang Y
Frontiers in immunology 2022
Increased TIGIT+PD‑1+CXCR5‑CD4+T cells are associated with disease activity in rheumatoid arthritis
Luo Q, Fu P, Guo Y, Fu B, Guo Y, Huang Q, Huang Z, Li J
Experimental and therapeutic medicine 2022
Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors.
Kim MJ, Hong KH, Lee BR, Ha SJ
Cancer Immunology, Immunotherapy 2022
V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy
Zhou X, Khan S, Huang D, Li L
Frontiers in immunology 2022
Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis
Li S, Li L, Pan T, Li X, Tong Y, Jin Y
Frontiers in immunology 2022
Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models
Franks SE, Fabian KP, Santiago-Sánchez G, Wolfson B, Hodge JW
OncoImmunology 2022
Emerging Targets in Clear Cell Renal Cell Carcinoma
Chen YW, Rini BI, Beckermann KE
Cancers 2022
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
Mendoza-Valderrey A, Alvarez M, De Maria A, Margolin K, Melero I, Ascierto ML
Cells 2022
Tumor immune checkpoints and their associated inhibitors.
Gao Z, Ling X, Shi C, Wang Y, Lin A
Journal of Zhejiang University. Science. B 2022
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Franzese O, Graziani G
Cancers 2022
Inflammatory Cytokines That Enhance Antigen Responsiveness of Naïve CD8+ T Lymphocytes Modulate Chromatin Accessibility of Genes Impacted by Antigen Stimulation
Quenum AJ, Santharam MA, Ramanathan S, Ilangumaran S
International journal of molecular sciences 2022
The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
Pawłowska A, Skiba W, Suszczyk D, Kuryło W, Jakubowicz-Gil J, Paduch R, Wertel I
Cancers 2022
Combined Blockade Of PD-1 and TIGIT is not Sufficient to Improve the Function Of CD8+ T-Cells in Chronic Lymphocytic Leukemia.
Hatefi F, Asgarian-Omran H, Hossein-Nataj H, Akbar A, Shekarriz R, Zaboli E, Janbabai G, Tehrani M
Asian Pacific Journal of Cancer Prevention 2022
The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis
Ma J, Pang X, Li J, Zhang W, Cui W
Frontiers in Oncology 2022
Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
Li H, Zhao A, Li M, Shi L, Han Q, Hou Z
Frontiers in immunology 2022
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
Boissière-Michot F, Chateau MC, Thézenas S, Guiu S, Bobrie A, Jacot W
Frontiers in immunology 2022
免疫检查点TIGIT在肺癌免疫治疗中的研究进展
2022
TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma
Eichberger J, Spoerl S, Spanier G, Erber R, Taxis J, Schuderer J, Ludwig N, Fiedler M, Nieberle F, Ettl T, Geppert CI, Reichert TE, Spoerl S
Biomedicines 2022
Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade
Sinha D, Moseley P, Lu X, Wright Q, Gabrielli B, Frazer IH, Cruz JL
Cancers 2022
Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients
Benitez Fuentes JD, Mohamed Mohamed K, de Luna Aguilar A, Jiménez García C, Guevara-Hoyer K, Fernandez-Arquero M, Rodríguez de la Peña MA, Garciía Bravo L, Jiménez Ortega AF, Flores Navarro P, Bartolome Arcilla J, Alonso Arenilla B, Baos Muñoz E, Delgado-Iribarren García-Campero A, Montealegre Sanz M, Sanchez-Ramon S, Perez Segura P
Frontiers in Oncology 2022
Designing Cancer Immunotherapies That Engage T Cells and NK Cells.
Kyrysyuk O, Wucherpfennig KW
Annual Review of Immunology 2022
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón MC, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mulé JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA
Clinical cancer research 2022

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 3 X users
Referenced in 64 patents
On 1 Facebook pages
Referenced in 1 Wikipedia pages
542 readers on Mendeley
See more details